Reed Jobs's venture firm Yosemite has grown from a startup to a 17-person operation in under three years, and it is now betting heavily on two converging forces: a patent cliff hitting blockbuster drugs simultaneously, and AI that Jobs says is no longer peripheral but central to how Yosemite operates.
The timing matters. When Jobs last spoke at TechCrunch Disrupt, biotech was still absorbing the post-pandemic crash. That window of weakness is closing, and the patent expiration cluster is opening new lanes for generics, biosimilars, and reformulations. Yosemite is positioned to move in that gap, and the AI tooling it has built around drug discovery is the reason Jobs admits the firm is scaling faster than he anticipated.
The full interview is worth reading for how Jobs frames AI's role in oncology investment, not as automation but as a filter for which bets are even worth making. That distinction is doing a lot of work in how Yosemite thinks about dealflow.
[READ ORIGINAL →]